• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XIN Minhang, ZHANG Sanqi. Advances in PI3Kδ selective inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(5): 503-510. DOI: 10.11665/j.issn.1000-5048.20160501
Citation: XIN Minhang, ZHANG Sanqi. Advances in PI3Kδ selective inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(5): 503-510. DOI: 10.11665/j.issn.1000-5048.20160501

Advances in PI3Kδ selective inhibitors

More Information
  • Phosphoinositide 3-kinase(PI3K), a key regulator in the PI3K/AKT/mTOR signaling pathway, plays a critical role in regulation of cell growth, differentiation, metastasis apoptosis, and angiogenesis processes. Abnormal activation of PI3K is closely related to the development of many types of human cancers. PI3Kδ is an important isoform of PI3K family, mainly expressed in leukocytes, which makes it an attractive target for the treatment of hematological malignancies. Great efforts in both industry and academia have been made to develop PI3Kδ selective inhibitors as anti-cancer agents. This review attempts to provide an overview of recent advances in the research of PI3Kδ selective inhibitors, fueling the progress of the ideal selective PI3Kδ inhibitors in the future.
  • [1]
    Fruman DA,Rommel C.PI3K and cancer:lessons,challenges and opportunities[J].Nat Rev Drug Disc,2014,13(2):140-156.
    [2]
    Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms,modes of activation and therapeutic targeting[J].Nat Rev Canner,2015,15(1):7-24.
    [3]
    Puri KD,Di Paolo JA,Gold MR.B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies[J].Int Rev Immunol,2013,32(4):397-427.
    [4]
    Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta:modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies[J].Front Immunol,2012,3:256.
    [5]
    Angulo I,Vadas O,Garcon F.Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage[J].Science,2013,342(6160):866-871.
    [6]
    Shao T,Wang J,Chen JG,et al.Discovery of 2-methoxy-3-phenylsufonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere[J].Eur J Med Chem,2014,75:96-105.
    [7]
    Wei M,Wang X,Song Z,et al.Targeting PI3Kδ:emerging therapy for chronic lymphocytic leukemia and beyond[J].Med Res Rev,2015,35(4):720-752.
    [8]
    Venable JD, Ameriks MK. Small molecule inhibitors of phosphoinositide 3-kinase(PI3K)δ and γ[J].Curr Top Med Chem,2009,9(8):738-753.
    [9]
    Norman P.Selective PI3Kδ inhibitors,a review of the patent literature[J].Expert Opin Ther Pat,2011,21(11):1773-1790.
    [10]
    Norman P.Evaluation of WO201313136076:two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729[J].Expert Opin Ther Pat,2013,24(4):471-475.
    [11]
    Norman P. Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma[J].Expert Opin Ther Pat,2014,24(5):603-607.
    [12]
    Markham A.Idelalisib:first global approval[J].Drugs,2014,74(14):1701-1707.
    [13]
    Fruman DA,Cantley LC.Idelalisib a PI3Kδ inhibitor for B-cell cancers[J].N Engl J Med,2014,370(11):1061-1062.
    [14]
    Okkenhaug K.Two birds with one stone:dual p110δ and p110γ inhibition[J].Chem Biol,2013,20(11):1309-1310.
    [15]
    TG Therapeutics.TG-1101(Ublituximab)references[EB/OL].http://www.tgtherapeutics.com/pipeline/publications.cfm.
    [16]
    Vakkalanka S,Viswanadha S,Gaudio E,et al.Dual PI3Kδ/γ inhibition by RP6530 induces apoptosis and cytotoxicity in B-lymphoma cells[J].Blood,2013,122(21):4411.
    [17]
    Cushing TD,Hao X,Shin Y,et al.Discovery and in vivo evaluation of(s)-N-(1-(7-fluoro-2-(pyridine-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine(AMG319)and related PI3Kδ inhibitors for inflammation and autoimmune disease[J].J Med Chem,2015,58(1):480-511.
    [18]
    Safina BS,Baker S,Baumgardner M,et al.Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis:taming CYP3A4 time-dependent inhibition[J].J Med Chem,2012,55(12):5887-5900.
    [19]
    Murray JM,Sweeney ZK,Chan BK,et al.Potent and highly selective benzimidazole inhibitors of PI3-kinase delta[J].J Med Chem,2012,55(17):7686-7695.
    [20]
    Safina BS,Sweeney ZK,Li J,et al.Identification of GNE-293,a potent and selective PI3Kδ inhibitor:navigating in vitro genotoxicity while improving potency and selectivity[J].Bioorg Med Chem Lett,2013,23(17):4953-1959.
    [21]
    Down K, Amour A, Baldwin IR, et al. Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase δ for the treatment of respiratory disease[J].J Med Chem,2015,58(18):7381-7399.
    [22]
    Haselmayer P,Camps M,Muzerelle M.Characterization of novel of PI3Kδ inhibitors as potentical therapeutics for SLE and lupus nephritis in pre-clinical studies[J].Front Immunol,2014,5:233.
    [23]
    Cushing TD,Metz DP,Whittington DA,et al.PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases[J].J Med Chem,2012,55(20):8559-8581.
  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]CHEN Yating, WU Yue, DENG Zixian, ZHANG Yunqing, WU Shixun, SHEN Bingzheng. Research progress of microneedle in promoting wound healing[J]. Journal of China Pharmaceutical University, 2024, 55(4): 557-564. DOI: 10.11665/j.issn.1000-5048.2023082303
    [3]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [4]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [5]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [6]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [7]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [8]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [9]WU Qu, HUO Meirong, ZHOU Jianping. Advances on novel drug delivery system[J]. Journal of China Pharmaceutical University, 2013, 44(2): 97-104. DOI: 10.11665/j.issn.1000-5048.20130201
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.
  • Cited by

    Periodical cited type(5)

    1. 刘梦婷,孙国祥. 格列齐特缓释片的剂量倾泻研究. 中国医药工业杂志. 2024(04): 565-570 .
    2. 周培培,孙春艳,侯晓虹. 雷诺嗪缓释片剂量倾泻方法学建立与验证. 沈阳药科大学学报. 2024(12): 1627-1633 .
    3. 刘新颖,许向阳,曾令高,毛文星,郑冬梅,高梓真. 盐酸羟考酮缓释片体外释药特性研究. 中国药业. 2023(16): 52-56 .
    4. 苗国力,郭洪涛,刘文玲,崔芹芹. 盐酸文拉法辛缓释胶囊的制备及释放度研究. 山东化工. 2023(17): 48-53 .
    5. 徐晓宏,陶铭,李飞,魏群,龚青. 缓控释微丸胶囊仿制药处方工艺研究的审评考虑. 现代药物与临床. 2023(12): 3139-3144 .

    Other cited types(0)

Catalog

    Article views (1408) PDF downloads (2696) Cited by(5)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return